Company Short-Term Debts: Lineage Cell Therapeutics (LCTX)

Public company logo of Lineage Corp (LCTX)

Lineage Cell Therapeutics (LCTX) specializes in regenerative medicine and the development of innovative cell-based therapies. This chart, serving as an assessment tool, shows the value of short-term liabilities at 0.00. Strict biomanufacturing regulations and colossal clinical trial costs are hindering business growth. However, holding an extensive patent portfolio in retinal restoration provides the company with a sustainable competitive advantage and long-term protection.

LCTX: Lineage Cell Therapeutics, Inc. Short-Term Debt 07/04/2022 - 10/29/2026

Lineage Corp - analytical breakdowns and key metrics (LCTX)

- price and consensus price forecast:
Price Chart Lineage Cell Therapeutics, Inc.|LCTX - Consensus Target
- market capitalization data:
Market Capitalization Lineage Cell Therapeutics, Inc.|LCTX - Real Price to Acquire Entire Company
- book capitalization data:
Book Value per Share Lineage Cell Therapeutics|LCTX - Total Stockholders' Equity|Market Value to Book Value Ratio lineagecell.com|LCTX - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Lineage Cell Therapeutics|LCTX - Long-Term Debt to Equity|Short-Term Debt to Equity Lineage Cell Therapeutics|LCTX - Company Total Debt Obligations|Debt to Book Capitalization Ratio Lineage Cell Therapeutics, Inc.|LCTX - Company Long-Term Debt|Company Short-Term Debts Lineage Cell Therapeutics
Fundamental company valuation:LCTX - Lineage Cell Therapeutics, Inc.
Mass-produced product of Lineage Cell Therapeutics

The resilience of Lineage Cell Therapeutics (LCTX) is based on strategic partnerships that offset negative cash flow from scientific operations. An analysis of short-term debt volume allows for an assessment of the business's dependence on external liquid financing. This metric aggregates all credit obligations with a maturity of up to one year. A decrease in this indicator signals a reduction in the debt load. This is a critical factor in determining the fair value of a biotechnological asset.

Competitors of Lineage Cell Therapeutics (LCTX)

MESO: Company Short-Term Debt|SRZN - Company Current Liabilities|CCEL (cryo-cell.com) - Company Short-Term Debts|FibroBiologics (FBLG) - Company Current Liabilities|Company Short-Term Debts LGVN (Longeveron Inc.)|Short-Term Debt BRTX|Company Short-Term Debt Creative Medical Technology (CELZ)